Consumer genetics-testing company 23andMe’s sales growth was hit by privacy concerns last year, its chief executive said, at the same time touting the company’s drug development pipeline that she hopes will power its next phase.
from WSJ.com: US Business https://on.wsj.com/2SJJyHO
via IFTTT
No comments:
Post a Comment